All In Biotech

NDA 022369 · Abbvie

Latisse

Bimatoprost · Topical · Prostaglandin Analog

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 26, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Dec 24, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

147

39 Phase 3, 7 recruiting

FAERS reports

11,267

1,810 serious, 132 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 1, 2024.

LATISSE ® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. LATISSE ® is a prostaglandin analog, indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. ( 1 )

Mechanism: Bimatoprost is a structural prostaglandin analog. Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LATISSE · BIMATOPROST 0.03% · SOLUTION/DROPS, TOPICAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Bimatoprost" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,432
  • ocular hyperaemia1,482
  • madarosis1,369
  • eye irritation1,024
  • eye pruritus965
  • erythema of eyelid901
  • eyelids pruritus482
  • eye swelling481
  • wrong technique in product usage process454
  • wrong technique in drug usage process384
  • eyelid oedema375
  • inappropriate schedule of drug administration373

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
20054
20068
200712
200821
2009397
20101,527
2011886
2012513
201366
201495
20151,039
20161,023
20171,070
2018834
2019698
2020635
2021505
2022400
2023596
2024394
2025302
2026232

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 248 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.